Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 8/20 | 0.53 |
| ▸ | PARP1 | P09874 | 4/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.49 |
| ▸ | RPS6KA2 | Q15349 | 6/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30172384 | 1.00 | RPS6KA3 (0.53) | RPS6KA3PARP1MAPKAPK2RPS6KA2HRH3 | |
| SCHEMBL30622473 | 0.90 | RPS6KA3 (0.65) | RPS6KA3MAPKAPK2RPS6KA2 | |
| SCHEMBL28028081 | 0.90 | RPS6KA3 (0.65) | RPS6KA3MAPKAPK2RPS6KA2 | |
| SCHEMBL7396812 | 0.83 | RPS6KA3 (0.43) | RPS6KA3PARP1RPS6KA2HRH3HTR2A | |
| SCHEMBL24187362 | 0.80 | RPS6KA2 (0.56) | RPS6KA3PARP1MAPKAPK2RPS6KA2HRH3 | |
| SCHEMBL19252882 | 0.80 | RPS6KA3 (0.56) | RPS6KA3MAPKAPK2RPS6KA2HRH3CYP2D6 | |
| SCHEMBL2160684 | 0.80 | HRH3 (0.54) | RPS6KA3PARP1MAPKAPK2RPS6KA2HRH3 | |
| SCHEMBL38652559 | 0.80 | HRH3 (0.52) | RPS6KA3PARP1MAPKAPK2RPS6KA2HRH3 | |
| SCHEMBL30967663 | 0.80 | RPS6KA3 (0.52) | RPS6KA3PARP1MAPKAPK2RPS6KA2HRH3 | |
| SCHEMBL19187485 | 0.80 | HRH3 (0.52) | RPS6KA3PARP1MAPKAPK2RPS6KA2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | claimed |
| EP-1960401-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | claimed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | claimed |
| WO-2007065820-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | claimed |
| EP-1750687-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2007-02-14 | — | — | EP | claimed |
| WO-2005105213-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | claimed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| CN-117510495-A | Pyridazine compounds for inhibiting NLRP3 | 万特斯治疗美国公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117500792-A | Pyridazine compounds for inhibiting NLRP3 | 万特斯治疗美国公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| CN-110621675-B | Tricyclic compounds useful for the treatment of proliferative diseases | 阿古诺治疗有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | disclosed |
| EP-1945305-A2 | INDOLE AND AZAINDOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRANE DISCOVERY S.R.L. (IT) | 2008-07-23 | — | — | EP | disclosed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | disclosed |
| WO-2007048847-A2 | INDOLE AND AZAINDOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | NIKEM RESEARCH S.R.L. (IT) | 2007-05-03 | — | — | WO | disclosed |
| EP-1750687-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005105213-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | IDO1, IDO2, INMT | RPS6KA3 1250/4885PARP1 426/4885MAPKAPK2 2539/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | RPS6KA3 1180/4885PARP1 230/4885MAPKAPK2 909/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | RPS6KA3 1180/4885PARP1 230/4885MAPKAPK2 909/4885 |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | IDO1, IDO2, INMT | RPS6KA3 954/4885PARP1 1883/4885MAPKAPK2 3875/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | RPS6KA3 1240/4885PARP1 3197/4885MAPKAPK2 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.